The tweet was deleted by the author.
But we saved everything 🙂.
Camp4 Therapeutics Corp participated in the fourth annual BioConnect Investor Conference hosted by H.C. Wainwright & Co., where CEO Josh Mandel-Brehm joined a fireside chat to present the company’s regRNA-targeting platform aimed at increasing gene expression for treating diseases such as SYNGAP1.
The event, covered under the #regRNA and #GeneExpression themes, showcased Camp4 Therapeutics Corp’s latest research initiatives and efforts to translate RNA science into therapeutic breakthroughs for rare neurological disorders.
Earlier this year, Camp4 Therapeutics released a preprint outlining its expanded regRNA catalog using Capture-seq technology for gene expression research. The company also participated in a SYNGAP1 Symposium to engage with families and provide updates on its regRNA-based therapy progress. These initiatives reflect ongoing efforts to advance RNA-targeting treatments for rare neurological diseases.